Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, double-masked, placebo-controlled, randomized, SAD/MAD trial to evaluate the safety, tolerability and systemic pharmacokinetics (PK) of DT-168 ophthalmic solution

Next Previous
Trial Profile

A Phase 1, double-masked, placebo-controlled, randomized, SAD/MAD trial to evaluate the safety, tolerability and systemic pharmacokinetics (PK) of DT-168 ophthalmic solution

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 14 May 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs DT 168 (Primary)
  • Indications Fuchs' endothelial dystrophy
  • Focus Adverse reactions

Most Recent Events

  • 07 May 2025 According to a Design Therapeutics media release, design reported favorable results from the Phase 1 SAD/MAD clinical trial of DT-168 in healthy volunteers at Eyecelerator at Park City 2025 in May.
  • 01 May 2025 Status changed from recruiting to completed, according to a Design Therapeutics media release.
  • 01 May 2025 Results presented in the Design Therapeutics Media Release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top